Failure to gain acceptance for OGM and diagnostic assays
Revenue depends on customers adopting the platform and using it routinely; weak adoption limits both instrument and consumable sales.
- Scope
- Core product and software revenue
- Materiality
- high
Bionano Genomics, Inc.
Bionano Genomics, Inc. develops optical genome mapping (OGM) systems, purification instruments, consumables, and analysis software used in genomics and cytogenomics workflows. The company also operates Bionano Laboratories, which provides diagnostic testing services, although it has been scaling back certain clinical service offerings. Its core commercial focus is on research-use-only systems sold to academic, government, clinical, pharmaceutical, biotechnology, and contract research customers. Bionano’s software stack includes VIA, which replaced NxClinical installations and combines OGM with NGS and microarray interpretation in a single workflow. The business is built around instrument placements, recurring consumables, and software subscriptions, with service revenue playing a smaller and declining role after the phase-out of some laboratory services.
−83,5 %
46,3 %
−92,6 %
−7,4 %
1.98
1.64
| % | |
|---|---|
| Instruments | 35% OGM and Ionic purification systems sold to laboratories for research-use applications. |
| Consumables | 30% Reagents and chips used to process samples on installed systems. |
| Software | 10% VIA subscription software for visualization, interpretation, and reporting of genomics data. |
| Services | 20% Diagnostic testing, customer sample evaluations, and related laboratory services. |
| Other service revenue | 5% Warranty, support, repair, and maintenance revenue tied to installed systems. |
Bionano sells primarily to laboratories that use genomics tools in research and translational workflows, rather than to...
- Academic and government research institutionsprimary
Buy OGM systems, consumables, and VIA software for research-use genomics and cytogenomics applications.
- Clinical laboratoriesprimary
Use the platform and software to support interpretation and reporting workflows in molecular pathology and cytogenomics.
- Pharmaceutical and biotechnology companiessecondary
Purchase systems and software for research, assay development, and genomic characterization.
- Contract research organizationssecondary
Use the instruments and software to support outsourced genomics testing and research programs.
- Diagnostic testing customersemerging
Buy laboratory services from Bionano Laboratories, though this business has been scaled back.
The company is headquartered in the United States and the disclosed customer base is centered on U.S...
- •Headquartered in the United States
- •U.S. sales are more direct and central to commercial execution
- •International sales depend heavily on distributors
- •Global customer base spans research and clinical labs
- •Limited/sole-source components can disrupt worldwide deliveries
- •No country-level revenue split was disclosed in the excerpts
Bionano’s stated strategic shift is to focus on driving utilization and adoption of OGM within its existing installed...
01
Drive utilization of the installed OGM baseshort-term
Recurring consumables and software revenue depend on customers using the systems more frequently.
02
Expand VIA software adoptionmedium-term
Software can increase workflow stickiness and broaden the company’s role in genomics interpretation.
03
Rationalize the services portfolioshort-term
Phasing out weak clinical offerings reduces distraction and focuses resources on core platform economics.
Bionano faces substantial commercialization risk because its business depends on market acceptance of OGM systems,...
Bionano Laboratories commercialization risk
Management disclosed that laboratory revenue has been insufficient to fund operations and certain offerings were phased out.
- Scope
- Service revenue
- Materiality
- high
Ongoing losses and capital needs
The company has incurred recurring losses and may need additional financing to support operations.
- Scope
- Liquidity and dilution risk
- Materiality
- high
Distributor dependence outside the United States
International sales rely on third-party partners, which can limit market access and execution quality.
- Scope
- Non-U.S. revenue growth
- Materiality
- medium
Single-source or limited-source components
Supply interruptions could delay instrument production and customer deliveries.
- Scope
- Instrument manufacturing and fulfillment
- Materiality
- medium
Revenue recognition across instruments, consumables, software, and services
Comparability of reported revenue and margins
Reagent rental arrangements
Timing of revenue and customer acquisition economics
Impairment of acquired intangibles and goodwill
Potential non-cash charges to earnings and equity
Warranty and other service reserves
Cost of revenue and operating expense volatility
NEOGENOMICS INC
NEO · Services-Testing Laboratories
NeoGenomics is a U.S.-based cancer diagnostics company that provides oncology testing and consultative pathology services to help clinicians identify, classify, and monitor cancer.
BIOMERICA INC
BMRA · In Vitro & In Vivo Diagnostic Substances
10x Genomics, Inc.
TXG · Laboratory Analytical Instruments
10x Genomics is a life sciences tools company that sells integrated workflows for high-resolution analysis of biological samples, combining instruments, proprietary consumables, and bundled software.
Boundless Bio, Inc.
BOLD · Pharmaceutical Preparations
SANGAMO THERAPEUTICS, INC
SGMOQ · Biological Products, (No Diagnostic Substances)
Sangamo Therapeutics is a U.S.-based genomic medicine company focused on developing therapies and enabling technologies built around zinc finger biology,…
Fulgent Genetics, Inc.
FLGT · Services-Medical Laboratories
: 11/08/2026